Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Becton, Dickinson and Company (BD) SEC filings page for ticker BDX provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a New Jersey–incorporated issuer with common stock listed on the New York Stock Exchange, BD files current reports on Form 8-K, annual and quarterly reports, proxy statements and other documents that give investors insight into its financial condition, governance and capital structure.
BD’s recent Form 8-K filings include disclosures on financial results, such as preliminary unaudited revenue and quarterly earnings press releases, as well as corporate events like executive transitions, board appointments and changes in credit facilities. For example, BD has reported the appointment of new directors, the planned transition of its chief financial officer role, and the execution of a third amended and restated revolving credit agreement that provides senior unsecured financing for general corporate purposes. Other 8-K filings describe temporary blackout periods under the BD 401(k) Plan related to a transaction involving Waters Corporation.
Investors can also review BD’s definitive proxy statement on Schedule 14A, which outlines matters for shareholder voting, board composition, executive compensation programs and strategic themes such as the BD2025 and Excellence Unleashed strategies. Debt-related filings, including listings of various series of notes and a Form 25 relating to the removal from listing of 0.034% Notes due 2025, help users understand BD’s capital markets activities. Common stock and several note issues remain registered and listed on the NYSE, as indicated in the filings.
On this page, Stock Titan presents BD’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, such as 10-K and 10-Q reports, 8-K event descriptions and proxy materials. Users can quickly identify information about BD’s revolving credit facilities, leverage covenants, executive changes, shareholder meetings and note listings, while still having the option to review the full original filings from EDGAR for detailed analysis.
Becton, Dickinson and Company (BDX) furnished a press release announcing financial results for its fourth fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to the report under Item 2.02.
The company notes that the release includes certain non-GAAP financial measures, with reconciliations and details presented in schedules accompanying Exhibit 99.1.
Becton, Dickinson and Company (BDX) director Carrie L. Byington reported an acquisition of derivative securities. On 11/04/2025, she acquired 34 rights to common stock under the BD Deferred Compensation Plan at a price of $178.71 per derivative security.
Following the transaction, she beneficially owns 1,675 derivative securities, held directly. Each right converts into one share of common stock. According to the plan terms, the securities are distributed after the director’s service ends or on dates the director specifies.
Becton, Dickinson and Company (BDX) reported a Form 4 for director Christopher Jones. On 11/04/2025, he acquired 168 derivative securities described as rights to common stock under the BD Deferred Compensation Plan, coded “A.” The filing lists a price of $178.71 for the derivative security.
Following this transaction, Jones beneficially owns 11,316 derivative securities on a direct basis. The securities convert to common stock on a one-for-one basis and are distributed following the end of his service as a director or on the date(s) he specifies. The filing notes that totals include rights acquired through dividend investment since the last report.
Becton Dickinson (BDX) reported an insider transaction by its EVP & President, Life Sciences. On 10/27/2025, the officer sold 57 shares of common stock at $186.01 per share. Following the sale, the officer beneficially owns 8,245 shares, held directly.
The filing notes the trade was made pursuant to a Rule 10b5-1 plan adopted on February 7, 2025, indicating a pre-set trading arrangement.
Becton, Dickinson and Company (BDX) filed a Form 144 for a proposed sale of 57 shares of common stock with an aggregate market value of $10,592.31. The planned sale is listed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of October 27, 2025.
The shares to be sold were acquired as Restricted Stock Units on August 20, 2025. Recent activity reported under a Rule 10b5-1 plan for Michael Feld includes 58 shares sold on September 26, 2025 for $10,499.74 and 57 shares sold on August 22, 2025 for $11,285.43.
Becton, Dickinson and Company (BDX) announced two updates. The company furnished a press release with preliminary unaudited revenue for its fourth quarter and full fiscal year ended September 30, 2025, provided as Exhibit 99.1.
BDX also disclosed a leadership transition. Executive Vice President and Chief Financial Officer Christopher J. DelOrefice informed the company on October 9, 2025, of his intention to resign effective December 5, 2025, to pursue a new professional opportunity. The company stated his departure is not due to any disagreement regarding financial statements, internal control, operations, policies or practices.
Upon his departure, Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, Vitor Roque, will serve as interim Chief Financial Officer and principal financial officer while a search for a permanent CFO is underway.
Michael Feld, EVP & President, Life Sciences at Becton Dickinson & Co (BDX), reported a sale of 58 shares of common stock at $181.03 per share on 09/26/2025, leaving him with 8,302 shares beneficially owned. The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 2, 2024.
Becton Dickinson & Co. (BDX) Form 144 shows a proposed sale of 58 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $10,474.22 and an approximate sale date of 09/26/2025 on the NYSE. The shares were acquired as Restricted Stock Units on 08/20/2025. The filing also discloses a prior 10b5-1 sale of 57 shares on 08/22/2025 with gross proceeds of $11,285.43. The form lists total shares outstanding as 286,627,469. Several filer contact fields and issuer identification fields are blank in the provided content.
Becton, Dickinson and Company filed an 8-K reporting a material event: the company entered into a Third Amended and Restated Credit Agreement dated September 16, 2025 among Becton, Dickinson and Company, other parties to the agreement, and Citibank, N.A. as administrative agent. The filing identifies the credit agreement as Exhibit 10.1 and includes Inline XBRL interactive data on the cover page. The report also reiterates the company’s registered securities, including its common stock (BDX) and several listed note series. The filing provides the existence and counterparty for the amended credit facility but does not disclose the agreement’s financial terms, covenants, maturity, or commitments within the provided text.
Claire Fraser, a director of Becton, Dickinson and Company (BDX), reported a sale of 917 shares of BDX common stock on 09/10/2025 at a reported price of $187.50 per share. After the sale, the reporting person beneficially owned 22,226 shares in a direct ownership form. The Form 4 was signed by Donna Kalazdy by power of attorney on 09/11/2025.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
